Kenyan Health Patient Information Leaflet
Vaccine / immunological product
active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards. Clinical selection for Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Vaccine / immunological product. Confirm site-specific dose, duration and monitoring before prescribing.
0.5mL, three vaccine doses administered at intervals of at least 4 weeks.
[Diphtheria] Local pain, low-grade fever, myalgia. Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products). [Pertussis] Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels. [Hepatitis B vaccine] Local pain, low-grade fever, myalgia. Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
Store as labelled. Keep out of reach of children.